[BRAF：病理学家最青睐的致癌基因] - Suppr

[BRAF: the pathologist's favorite oncogene].

作者信息

Sabourin Jean-Christophe

机构信息

Service de pathologie, pôle de biologie clinique, pathologie, physiologie, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France.

出版信息

Ann Pathol. 2013 Dec;33(6):373-4. doi: 10.1016/j.annpat.2013.11.001.

DOI:10.1016/j.annpat.2013.11.001

PMID:24331718

Abstract

摘要

相似文献

[BRAF: the pathologist's favorite oncogene].

Ann Pathol. 2013 Dec;33(6):373-4. doi: 10.1016/j.annpat.2013.11.001.

[Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].

Ann Pathol. 2013 Dec;33(6):375-85. doi: 10.1016/j.annpat.2013.09.003. Epub 2013 Oct 31.

RASopathic alopecia: hair changes associated with vemurafenib therapy.

J Am Acad Dermatol. 2015 Apr;72(4):738-41. doi: 10.1016/j.jaad.2015.01.011.

[Adverse skin reactions induced by BRAF inhibitors: a systematic review].

Ann Dermatol Venereol. 2013 Aug-Sep;140(8-9):510-20. doi: 10.1016/j.annder.2013.02.031. Epub 2013 Jun 19.

Toxic epidermal necrolysis induced by vemurafenib.

Actas Dermosifiliogr. 2015 Oct;106(8):682-3. doi: 10.1016/j.ad.2015.03.008. Epub 2015 Jun 4.

Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.

J Drugs Dermatol. 2015 May;14(5):509-10.

Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.

Exp Dermatol. 2016 May;25(5):394-5. doi: 10.1111/exd.12975.

The genesis of Zelboraf: targeting mutant B-Raf in melanoma.

J Cell Biol. 2012 Oct 1;199(1):15-9. doi: 10.1083/jcb.201205167.

The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.

J Invest Dermatol. 2010 Nov;130(11):2669-71. doi: 10.1038/jid.2010.177. Epub 2010 Jun 24.

Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.

Melanoma Res. 2013 Oct;23(5):373-80. doi: 10.1097/CMR.0b013e328363ed92.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[BRAF: the pathologist's favorite oncogene].

Ann Pathol. 2013 Dec;33(6):373-4. doi: 10.1016/j.annpat.2013.11.001.

[Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].

Ann Pathol. 2013 Dec;33(6):375-85. doi: 10.1016/j.annpat.2013.09.003. Epub 2013 Oct 31.

RASopathic alopecia: hair changes associated with vemurafenib therapy.

J Am Acad Dermatol. 2015 Apr;72(4):738-41. doi: 10.1016/j.jaad.2015.01.011.

[Adverse skin reactions induced by BRAF inhibitors: a systematic review].

Ann Dermatol Venereol. 2013 Aug-Sep;140(8-9):510-20. doi: 10.1016/j.annder.2013.02.031. Epub 2013 Jun 19.

Toxic epidermal necrolysis induced by vemurafenib.

Actas Dermosifiliogr. 2015 Oct;106(8):682-3. doi: 10.1016/j.ad.2015.03.008. Epub 2015 Jun 4.

Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.

J Drugs Dermatol. 2015 May;14(5):509-10.

Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.

Exp Dermatol. 2016 May;25(5):394-5. doi: 10.1111/exd.12975.

The genesis of Zelboraf: targeting mutant B-Raf in melanoma.

J Cell Biol. 2012 Oct 1;199(1):15-9. doi: 10.1083/jcb.201205167.

The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.

J Invest Dermatol. 2010 Nov;130(11):2669-71. doi: 10.1038/jid.2010.177. Epub 2010 Jun 24.

Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.

Melanoma Res. 2013 Oct;23(5):373-80. doi: 10.1097/CMR.0b013e328363ed92.

[BRAF: the pathologist's favorite oncogene].

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献